Fri, Sep 19, 2014, 5:29 AM EDT - U.S. Markets open in 4 hrs 1 mins

Recent

% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • thirdmeinvestor thirdmeinvestor Mar 30, 2013 9:12 AM Flag

    test

    Somehow I cannot post the blog on Next generation drug against hep C. I'll try to copy the conclusion of the article in the New England Journal of Medicine March 27th issue.

    CONCLUSIONS
    The use of miravirsen in patients with chronic HCV genotype 1 infection showed prolonged dose-dependent reductions in HCV RNA levels without evidence of viral resistance. (Funded by Santaris Pharma; ClinicalTrials.gov number, NCT01200420.)

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Santaris is not the only company working on anti-miR122 oligonucleotides, but their work hit the NEJM first.

      In a human trial, only 5 shots over a 4 wk period cleared HCV without serious side effects in 5 out of 9 who received the highest monotherapy dose of anti-miR122 oligonucleotide drug, Miravirsen. miR122 is a non-coding RNA abundant in the human liver and this RNA is required for the replication of HCV RNA. The reason HCV cannot replicate outside a liver is that the non-liver cells do not have miR122.

      • 1 Reply to thirdmeinvestor
      • Thanks Third. FYI the new yahoo message board blocks any post containing a link, to you need to type in the web site rather than cut a paste it in your message or insert relavant sections of the article into your posts as you did above. This NEJM article shows an interesting new mechanism of action and one more potential competitor for everyone interested in this "race" to a better hep C treatment regiemn to consider. What's your take on the ION 1 press release from last week from Gilead?

 
VRTX
97.35+2.85(+3.02%)Sep 18 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.